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ABSTRACT
Introduction: Hearing loss is a major public health
concern, affecting over 11 million people in the UK.
While hearing aids are the most common clinical
intervention for hearing loss, the majority of people that
would benefit from using hearing aids do not take them
up. Recent technological advances have led to a rapid
increase of alternative listening devices to conventional
hearing aids. These include hearing aids that can be
customised using a smartphone, smartphone-based
‘hearing aid’ apps, personal sound amplification
products and wireless hearing products. However, no
systematic review has been published evaluating
whether alternative listening devices are an effective
management strategy for people with hearing loss.
Methods and analysis: The objective of this
systematic review is to assess whether alternative
listening devices are an effective intervention for adults
with hearing loss. Methods are reported according to the
Preferred Reporting Items for Systematic reviews and
Meta-analyses Protocols (PRISMA-P) 2015 checklist.
Retrospective or prospective studies, randomised
controlled trials, non-randomised controlled trials, and
before-after comparison studies will be eligible for
inclusion. We will include studies with adult participants
(≥18 years) with a mild or moderate hearing loss. The
intervention should be an alternative listening device to a
conventional hearing aid (comparison). Studies will be
restricted to outcomes associated with the
consequences of hearing loss. We will search relevant
databases to identify published, completed but
unpublished and ongoing trials. The overall quality of
included evidence will be evaluated using the GRADE
system, and meta-analysis performed if appropriate.
Ethics and dissemination: No ethical issues are
foreseen. The findings will be reported at national and
international conferences, primarily audiology, and ear,
nose and throat, and in a peer-reviewed journal using the
PRISMA guidelines.
Review registration number: PROSPERO
CRD4201502958.
INTRODUCTION
Hearing loss affects over 11 million people in
the UK (1 in 6 of the population), and is
expected to rise to 15.5 million by 2030
given the ageing population profile.1 If
untreated, hearing loss can make communi-
cating with others difficult, which may lead
to social isolation and withdrawal, mental
illness (eg, anxiety, depression), and reduced
quality of life.2 3 Hearing loss is associated
with an increased risk of dementia and mor-
tality in older adults.4 5 Unemployment rates
are higher in people with hearing loss,
costing the UK an estimated £24.8 billion in
lost economic output each year.6
Consequently, hearing impairment is a major
public health concern, having a significant
impact on the individual, significant others
and to society more generally.
The most prevalent degree of hearing loss
can be defined as mild-to-moderate, affecting
92% of all adults with hearing loss in the UK.1
Hearing sensitivity can be assessed according
to pure-tone thresholds across five different
octave frequencies (0.25, 0.5, 1, 2, 4 kHz),
with mild hearing loss indicated as a 20–
40 dB hearing level (HL) and moderate as a
Strengths and limitations of this study
▪ The protocol poses a clearly formulated research
question identified and prioritised by key stake-
holders in a recent James Lind Alliance Priority
Setting Partnership for mild-to-moderate hearing
loss.
▪ The systematic review will be the first to pool
together evidence assessing the effectiveness of
alternative listening devices to conventional
hearing aids.
▪ Studies assessing analogue (as opposed to
digital) hearing aids will be excluded, as they are
an obsolete technology.
▪ We will only include studies with adults
(≥18 years), since audiological characteristics
differ substantially between children and adults.
▪ Grey literature and dissertation abstracts will not
be searched.
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41–70 dB HL average in the better hearing ear.7 The
most common clinical intervention for people with
hearing loss is hearing aids, yet up to 60% of adults with
hearing loss who would benefit from hearing aids do
not take them up.8 9 Furthermore, although the preva-
lence and severity of hearing loss gradually increases
from the age of around 55 years, hearing aids are not
typically adopted until people reach, on average, their
mid-70s. The majority of first-time hearing aid users sub-
sequently report that they have had a hearing problem
for around 10 years or more before seeking help.10 Of
particular relevance here is that the older people are
when they receive hearing aids, the greater difficulties
they may have adapting to and maintaining them.10 11
Conversely, hearing aid fitting from an earlier age can
result in substantial benefits (ie, more years of use,
better use) compared with age-matched individuals
fitted with hearing aids at a later age.10 It is therefore
imperative that effective strategies are found that will
promote the management of hearing loss from the earli-
est age possible, and so minimise the negative conse-
quences associated with untreated hearing loss.
Conventional hearing aids do not restore hearing but
make sounds more audible through electroacoustic amp-
lification. Hearing aids are regulated medical devices
that deliver sound into the ear canal via air or bone con-
duction. Bone conduction hearing aids and bone
anchored hearing aids (BAHAs) are for people that
have a conductive hearing loss (ie, sound cannot pass
freely through the outer and middle ear) and so are
unable to wear air conduction hearing aids. Rather than
sound from the hearing aid being delivered through the
ear canal, sounds are sent through the skull directly to
the inner ear. Depending on the technology they use to
process sounds, hearing aids can be described as ‘ana-
logue’ or ‘digital’, and can be worn behind-the-ear
(BTE), in-the-ear (ITE) or receiver-in-the-canal (RIC).
In the UK, hearing aids can be obtained and fitted free
of charge from a qualified hearing healthcare profes-
sional trained in audiology via the National Health
Service (NHS) or a registered hearing aid dispenser in
the private sector.
It may be taken for granted that hearing aids are an
effective intervention for hearing loss. Indeed, a previ-
ous systematic review of literature published up to
August 2004 suggested that hearing aids improve
hearing-related quality of life, alleviating activity limita-
tions and participation restrictions associated with
hearing loss through improved communication.
Nevertheless, the quality of the evidence was poor, with
only two randomised controlled trials (RCTs) eligible to
be included.12 This systematic review is currently being
updated in a Cochrane review of RCTs and
quasi-randomised controlled clinical trials.13
Recent advances in technology have also led to a
rapid increase of innovative alternative devices that
provide similar functionality (ie, amplification of sound)
to conventional hearing aids.14 Alternative listening
devices are of clear interest to patients and practitioners,
reflected in the unanswered research question ‘Can new
technologies replace hearing aids?’, ranked by patients
and healthcare professionals as the fifth topmost
‘unanswered question’ in the recent James Lind Alliance
Priority Setting Partnership for mild-to-moderate
hearing loss.15 As a consequence, the Cochrane review13
alongside a registered systematic review on alternative
listening devices will provide up-to-date high-level
evidence on the effectiveness of a wide range of
listening devices for adults with mild-to-moderate
hearing loss.
Alternative devices currently available include: (1)
‘made-for-smartphone’ hearing aids, which allow users
to adjust and personalise their hearing aid settings with
their smartphone; (2) smartphone apps (Android and
Apple OS X), whereby a smartphone or tablet com-
puter can act as a hearing aid when paired with wire-
less Bluetooth earphones or earbuds; (3) self-fitting
personal sound amplification products (PSAPs) that
provide an ‘off-the-shelf’ alternative to hearing aids; (4)
wireless hearing products that enhance the use of
hearing aids so that they can be connected to add-
itional electronic devices such as mobile phones, MP3
players or televisions via frequency modulation systems
or Bluetooth. Alternative listening devices may be par-
ticularly appealing to users in comparison to conven-
tional hearing aids because of their convenience and
accessibility, providing additional functionality, such as
listening to music, video gaming or watching televi-
sion.16 Convenience and ease of access of interventions
are key factors influencing rehabilitation decisions in
people with hearing loss.17–19 Moreover, digital literacy
skills continue to rise in 55–74 years old (2011=68%;
2013=76%; 2015=81%),20 suggesting that digital skills
would not be a barrier to using the alternative devices
described. Moreover, alternative listening devices may
be an effective management strategy for hearing loss.
For example, when compared with conventional
hearing aids, smartphone-based hearing aid apps have
been shown to provide similar levels of amplification,
improved speech-in-noise performance and greater self-
reported benefit.21 In addition, the use of alternative
listening devices may promote earlier intervention, in
addition to facilitating clinical help seeking.22 One
potential explanation for these findings is that alterna-
tive listening technologies not only raise awareness of
the consequences of hearing loss, but also increase self-
efficacy (or confidence) to seek clinical
rehabilitation.22
To date, no systematic review has been published that
specifically evaluates the quality of evidence concerning
whether alternative listening devices are an effective
intervention for people with hearing loss. This is import-
ant because a high-quality, impartial body of evidence is
necessary to determine whether alternatives could be
adopted and/or recommended to people with hearing
loss. There is also a strong clinical need to determine
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the effectiveness of alternative listening devices to con-
ventional hearing aids, particularly given that, in the
UK, the majority of adults with hearing loss have difficul-
ties accessing them. One significant barrier to access is
that up to 50% of adults who have hearing loss are not
referred onwards to hearing healthcare professional by
their general practitioner.10 Furthermore, at present,
one clinical commissioning group in the UK no longer
provides hearing aids for people with mild-to-moderate
hearing loss.
The primary objective of this study is to systematically
review existing evidence that assesses whether alternative
listening devices to conventional hearing aids are an
effective intervention for adults with hearing loss. We
define alternative devices as both standalone products
and devices that provide additional features to a conven-
tional hearing aid. Secondary objectives are to assess
feasibility (eg, accessibility, usability, acceptability,
take-up, adherence) of alternative listening devices. It is
anticipated that this review will provide an evidence base
to help inform future feasibility and effectiveness trials
on alternative devices, an approach consistent with the
Medical Research Council’s (MRC’s) guidelines for
evaluating complex healthcare interventions.23
METHODS AND ANALYSIS
The methods of the systematic review are reported
according to the Preferred Reporting Items for
Systematic reviews and Meta-analyses Protocols
(PRISMA-P) 2015 checklist.24 25 Subheadings corres-
pond to the recommended items to address in a system-
atic review protocol according to the checklist. The
systematic review will be led by DWM, and specific roles
of the named authors of the review protocol are speci-
fied in each section where appropriate.
Eligibility criteria
The inclusion criteria are specified according to the
Participant, Intervention, Comparison, Outcome and
Setting (PICOS) study characteristics.
Types of study: Retrospective or prospective studies,
RCTs, non-RCTS, and before-after comparison studies
will be eligible for inclusion. Articles reporting expert
opinions, practice guidelines, case reports, case series,
conference abstracts and book chapters will be excluded.
Participants: We will include adults (≥18 years) with a
mild or moderate hearing loss (average hearing thresh-
old across octave frequencies 0.25–4 kHz ≥20 and
≤70 dB HL7), given that audiological characteristics
differ substantially between children and adults.26
Studies that include both children (<18 years) and
adults will not be included unless data are reported sep-
arately. If the hearing threshold is not specified, the
study author will be contacted for further clarification. If
hearing threshold data are not reported and cannot be
obtained, studies will be included where the mean
average hearing threshold reported falls within the
range of either mild (between 20 and 40 dB HL) or
moderate hearing loss (between 41 and 70 dB HL).
Studies will be included if only qualitative descriptions
of hearing threshold are provided with no audiometric
data, but they will not be included in the meta-analysis.
Bilateral and unilateral sensorineural, conductive and
mixed hearing losses will be included.
Intervention: Any alternative listening device to a con-
ventional hearing aid will be included. Alternative
devices can be standalone products that are not regu-
lated medical devices (eg, smartphone app, self-fitting
PSAP) or devices that provide additional features to a
conventional hearing aid (eg, ‘made-for-smartphone’
hearing aid, wireless hearing product). Alternative listen-
ing devices should aim to improve hearing and commu-
nication outcomes in people with hearing loss through
the amplification of external sound sources.
Comparison: Comparisons can be inactive (eg, unaided,
no treatment, usual care, waiting list) or active (eg, con-
ventional hearing aid, BAHA, other alternative listening
device). Conventional hearing aids are defined as a
regulated medical device that delivers electroacoustic
amplification via air or bone conduction, irrespective of
where they are worn (BTE, ITE, RIC). Studies with ana-
logue hearing aid instruments (as opposed to digital)
will not be included. In 2000, the Modernising Hearing
Aid Services programme was introduced, whereby all
NHS patients are now provided digital hearing aids as
standard. Analogue hearing aids are therefore an obso-
lete technology.
Outcome measures: As this review is concerned primarily
with the effectiveness of alternative listening devices,
studies will be restricted to outcomes associated with the
consequences of hearing loss. Primary outcomes will
include one or more of the following: (1) behavioural
measures of speech intelligibility (eg, intelligibility of syl-
lables, words or sentences presented in quiet or in
noise); (2) hearing-specific health-related quality of life,
where participation is the key domain, measured using
any self-report questionnaire (eg, Hearing Handicap
Inventory for the Elderly, HHIE27); and (3) adverse
effects, reported by the patient as pain, discomfort, ten-
derness, skin irritation or ear infection as a consequence
of device fitting. Secondary outcomes will include any of
the following self-report outcomes: (1) health-related
quality of life (eg, Health Utilities Index Mark 3,
HUI-328); (2) listening ability (eg, Abbreviated Profile of
Hearing Aid Benefit, APHAB29); (3) cognition (eg,
working memory); (4) adverse effect, noise-induced
hearing loss (eg, due to overamplification from inappro-
priate hearing aid fitting); and (5) feasibility (eg, usabi-
lity, adherence).
Settings: Any research settings will be included.
Information sources
The search protocol and methods have been developed
by a medical information specialist (Dr Farhad
Shokraneh, Systematic Review Solutions Limited).
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A systematic search strategy will be employed to iden-
tify articles that meet eligibility for inclusion. We will
search CINAHL (via EBSCOhost), Cochrane Library,
EMBASE (via Ovid SP), MEDLINE (via Ovid SP),
PubMed, Scopus, Citations Indexes of Web of Science,
ISRCTN Registry, ClinicalTrials.Gov and WHO
International Clinical Trials Registry Platform (ICTRP)
to identify published, completed but unpublished and
ongoing trials. All database searches will be completed
in 1 day and with no time, language, document type or
publication status limitations.
In addition, hand searching the past 6 months of pub-
lications from key audiology journals will be undertaken
to ensure that any recently published articles are identi-
fied. Additional information will be identified manually
through snowballing of the reference lists from included
studies, as well as screening of related articles by short-
listed authors, to identify any relevant articles that may
not have been returned by the initial database searches.
Searches will be repeated 1 month prior to submission
for publication to ensure that any newly published
studies are included. Contact with study authors will be
permitted to ascertain whether any studies are ongoing.
Manual searches and personal author contact will con-
tinue up to the end of the data collection phase.
At the end of study selection process, search strategies
for each database will be reported in a reproducible and
replicable way, and a PRISMA flow diagram will be
presented.
Search strategy
The search terms were collected based on free text and
controlled vocabularies (Medical Subject Headings
(MeSH), Excerpta Medica Tree (EMTREE) and
CINHAL Headings), expert opinion, literature review
and checking the test search results.
We will use the following search strategy for PubMed,
which will be adapted for other databases:
(‘Hearing Loss’[MeSH] OR Hypoacus*[tiab] OR
‘Hearing Loss’[tiab] OR ‘Hearing Losses’[tiab]
OR ‘Hearing Impairment’[tiab] OR ‘Hearing
Impairments’[tiab] OR Deaf*[tiab] OR ‘Hearing
Problem’[tiab] OR ‘Hearing Problems’[tiab]) AND
(‘Hearing Aids’[MeSH:NoExp] OR ((Auditory[tiab]
OR Hearing[tiab] OR Amplif*[tiab] OR Listening[tiab]
OR Audible[tiab] OR Hearable[tiab] OR Aural[tiab] OR
Audio*[tiab]) AND (Prosthes*[tiab] OR Device*[tiab]
OR Aid[tiab] OR Aids[tiab] OR Product[tiab] OR
Products[tiab])) OR ‘Ear Mold’[tiab] OR ‘Ear
Molds’[tiab] OR Conventional[tiab] OR Unaided[tiab]
OR ‘No Treatment’[tiab] OR ‘Control Group’[tiab] OR
‘Usual Care’[tiab] OR ‘Waiting List’[tiab] OR Waitlist
[tiab] OR ‘Treatment as Usual’[tiab] OR ‘Usual
Treatment’[tiab] OR Routine[tiab] OR ‘Care as
Usual’[tiab]) AND (‘Wireless Technology’[MeSH] OR
‘Smartphone’[MeSH] OR ‘Mobile Applications’[MeSH]
OR Alternative*[tiab] OR Premium[tiab] OR Digital[ti]
OR Smartphone*[tiab] OR ‘Smart Phone’[tiab] OR
‘Smart Phones’[tiab] OR iPhone[tiab] OR Wireless[tiab]
OR ‘FM System’[tiab] OR ‘Frequency Modulation’[tiab]
OR Bluetooth[tiab] OR ‘Assistive Listening’[tiab] OR
‘Mobile App’[tiab] OR ‘Mobile Apps’[tiab] OR ‘Mobile
Application’[tiab] OR ‘Mobile Applications’[tiab]
OR ‘Self-Fitting’[tiab]) AND (‘Clinical Trials as Topic’
[MeSH] OR Randomized Controlled Trial[pt] OR
Controlled Clinical Trial[pt] OR Pragmatic Clinical Trial
[pt] OR Clinical Trial[pt] OR Observational Study[pt]
OR Multicenter Study[pt] OR ‘Non-Randomized
Controlled Trials as Topic’[MeSH] OR Randomized
[tiab] OR Randomised[tiab] OR Nonrandomized[tiab]
OR Nonrandomised[tiab] OR ‘Quasi Experimental’
[tiab] OR Placebo[tiab] OR Randomly[tiab] OR Trial
[tiab] OR Trials[tiab] OR RCT*[tiab] OR Groups[tiab]
OR ‘Cross-Over Studies’[MeSH] OR ‘Cross Over’[tiab]
OR Crossover[tiab] OR ‘Controlled Before-After
Studies’[MeSH] OR ‘Before After’[tiab] OR ‘Before
and After’[tiab] OR ‘CBA Study’[tiab] OR ‘CBA
Studies’[tiab] OR ‘Cohort Studies’[MeSH] OR Cohort
[tiab] OR Concurrent[tiab] OR Incidence[tiab] OR
‘Follow Up’[tiab] OR Followup[tiab] OR Longitudinal
[tiab] OR Prospective[tiab] OR Retrospective[tiab] OR
‘Case-Control Studies’[MeSH] OR ‘“Case Control”’[tiab]
OR ‘Case Comparison’[tiab] OR ‘Case Compeer’[tiab]
OR ‘Case Base’[tiab] OR Retrospective[tiab]).
Data management (DWM and ABB)
DWM will be responsible for data management using
Covidence online software (https://http://www.
covidence.org/). All identified articles will be recorded
electronically, and can be tracked throughout the data
screening and extraction process. Reasons for exclusion
will be noted and included articles allocated a unique
study ID code so that the record can be linked to the
corresponding full text and data collection sheet.
Selection process (DWM, ABB and MAF)
DWM and ABB will independently screen all relevant
references to decide eligibility according to the inclusion
and exclusion criteria by reading the title and abstract.
The full text will be obtained for articles that appear to
meet the inclusion criteria or where there is any uncer-
tainty (ie, insufficient information to make a clear deci-
sion). Where necessary, study authors will also be
contacted for additional information to resolve questions
concerning eligibility. Discrepancies will be adjudicated
by MAF.
Data collection process (DWM, ABB, JX and MAF)
We plan to use a standardised data collection form con-
structed via Covidence. Detailed guidance notes will be
devised by DWM prior to starting the review. The guid-
ance notes and data collection form will be piloted by
DWM and ABB, and revised if necessary before the
review to ensure consistency. Data collection will be con-
ducted by DWM and ABB independently, but in dupli-
cate for every record included. Study authors will be
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contacted to resolve any uncertainties. MAF and JX will
sample a subset (∼10%) of data collection sheets for
each author to confirm consistency of approach. All
authors will resolve any disagreement through discussion.
Data items
The data collection form will include a list of fields
given in table 1, consisting of study type, type of inter-
vention and comparison, outcome measures and statis-
tical tests. If any information is not reported, this will be
recorded in the corresponding field. We will contact the
corresponding author of any included study to obtain
missing data. If data can only be estimated, this will be
approximated from figures.
Risk of bias in individual studies (DWM and ABB)
DWM and ABB will independently assess risk of bias of
each included study with the Cochrane Risk of Bias
Tool, which rates the studies as ‘high risk’, ‘low risk’ or
‘unclear risk’ in the following six domains: sequence
generation, allocation concealment, blinding of partici-
pants and outcome assessment, incomplete outcome,
selective reporting and other bias. The overall quality of
the evidence will be evaluated using the GRADE
system.30 Scores on five principal domains will be used
to assess the quality of the evidence: (1) limitations in
design; (2) inconsistency of results; (3) indirectness of
the evidence; (4) imprecision of results and (5) a high
probability of publication bias. The quality of the data
starts at ‘high’ and reduces by a level for each of the
factors not met.
Data synthesis (DWM and JX)
For binary data, we will calculate risk ratio with 95% CI
where possible. For continuous data, we will calculate
mean difference (MD) with 95% CI where the studies
use the same outcome measures; otherwise, we will
instead use standardised MD with 95% CI. If summary
effects are reported, we will analyse these using generic
inverse variance and report the effect estimates with its
95% CI.
In the absence of meta-analysis, primary and second-
ary outcomes will be assessed at the individual study
level, with the main study findings examined through
narrative synthesis.
Assessment of heterogeneity
Heterogeneity across studies will be examined using I2
statistic. If I2 is >50%, we will explore potential statistical,
clinical or methodological causes for heterogeneity
through subgroup analysis. We will not pool studies if I2
exceeds 60%,31 but will present the data through narra-
tive synthesis. For robustness, both random-effects and
fixed-effects models will be used on the primary
outcome measures.
Assessment of reporting biases
Funnel plots will be used to estimate the influence of
unpublished papers on the overall effects (ie, publica-
tion bias).
Subgroup analysis
If heterogeneity is identified, subgroup analyses will
assess the impact of participant age, gender, degree of
hearing loss and the presence of comorbidity. Age will
be defined as older adults (≥55 years) and younger
adults (<55 years) since people with age-related hearing
loss are typically 55 years and older, which is also the age
eligibility threshold adopted by the services specification
developed by the UK Department of Health.32 If a study
reports males and females separately, it will contribute
to both subgroups. If a study includes only one gender,
it will be entered entirely into the appropriate subgroup.
If a study reports a mixed group, it will not be included
in the subgroup analysis. Degree of hearing loss will be
classified according to better ear hearing thresholds as
Table 1 Data items for the systematic review of trials on
the effectiveness of alternative listening devices to
conventional hearing aids
General information Study ID
Study title
Reference citation
Corresponding author and
contact details
Date of publication
Study eligibility Peer reviewed
English as first language
Type of study
Randomised controlled trial
Non-randomised controlled trial
Before and after studies
Other
Participants
Age range
Gender
Hearing loss
Health-related comorbidity
Type of intervention (all arms)
Types of comparison
Types of outcome
Primary outcome
domains
Speech intelligibility
Hearing-specific health-related
quality of life
Adverse effects (pain)
Secondary outcome
domains
Health-related quality of life
Listening ability
Cognition
Adverse effect (noise-induced
hearing loss)
Feasibility
Results and statistical
tests
Risk of bias assessment (see Risk of bias in individual
studies section)
Other information (this optional field will be used to record
further comments that may be deemed informative)
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either mild or moderate. Comorbidity will be defined as
any additional disease or disorder (behavioural, mental)
co-occurring with hearing loss. Each comorbid disorder
must be reported separately to contribute to the appro-
priate subgroup for analysis.
Ethics and dissemination (DWM and MAF)
No ethical issues are foreseen. The finding will be reported
at national and international conferences and meetings,
primarily audiology and ENT (DWM), and in a peer-
reviewed journal using the PRISMA guidelines (http://
www.prisma-statement.org/; DWM and MAF). A public and
patient involvement representative will be involved in dis-
seminating the outcomes of the review through print and
events aimed at non-specialist audiences.
Twitter Follow David Maidment at @DavidWMaidment
Collaborators Dr Farhad Shokraneh (Information Specialist, Systematic
Review Solutions Limited, Nottingham, UK).
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